NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
17/02/2026
Voltar para busca
Dado oficial do USPTO
GENFAR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
17/02/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 35
Data de depósito
17/04/2024
Data de registro
17/02/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/02/2026
Última transação
17/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
5
Tipo de titular
99
Localização do titular
Bogotá D.C., CO
Examinador
ABID, NABEELA
Unidade examinadora
O50
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized word "GENFAR" in red.
Titulares e representantes
Titulares
Genfar S.A.
Representantes
Stacy J. Grossman Law Office of Stacy J. Grossman PLLC
Classificação técnica
Classes Nice
Classe 5Classe 35
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical products of chemical synthesis and biologics for human use for the prevention and treatment of acute and chronic diseases for different age groups relating to the nervous systemcardiovascular systemrespiratory systemendocrine systemdigestive systemgenitourinary systemmusculoskeletal systemsensory systemshematopoietic systemimmune system; Pharmaceutical products in the form of prescription and non-prescription drugspillstabletscapsulesgranulatessachetsdropssyrupsinjectablesinhalerspatchescreamsgelssuppositoriesovulesimplantsany pharmaceutical form that allows adequate administration of the drugall for the prevention and treatment of chronic diseases for different age groups relating to the nervous systemcardiovascular systemrespiratory systemendocrine systemdigestive systemgenitourinary systemmusculoskeletal systemsensory systemshematopoietic systemimmune system; Pharmaceutical preparations for the treatment and prevention of acute and chronic diseases of the nervouscardiovascularrespiratoryendocrinedigestivegenitourinarymusculoskeletalsensoryhematopoieticimmune systems; drugs in the nature of pharmaceutical preparations for the treatment of infections caused by bacteriavirusesfungiparasitesother germs; Chemical and biological preparations for medical and pharmaceutical uses for the treatment and prevention of acute and chronic diseases relating to infectious diseasesneurological diseasespsychiatric conditionsendocrinological diseasesdigestive diseasescardiovascular diseasesrenal diseasesrespiratory diseasessense organ diseasesmusculoskeletal diseasesmale and female reproductive organ diseases relating to contraceptivesimmunological diseasesallergic conditionsinflammatory diseasesskin and adnexa dermatological diseasesoncological conditionshematopoietic diseases; Vaccines; Baby food; Medical plasters; Dressing materialsmedical dressings; Disinfectants; Vitamins; Vitamin preparations; Food supplements for medicinal purposes; Mineral food supplements for medicinal purposes; Nutritional supplements; Herbal preparations for medicinal purposes; Food supplements containing proteincarbohydratesfatfiber and micronutrients in the form of vitaminsmineral supplementsamino acid preparations for medicinal purposes and fatty acids for medicinal purposes
Classe 35
Business representative services in the nature of independent sales representativesimport-export agenciesall in the fields of pharmaceutical productspharmaceutical preparationsmedicines for human and veterinary healthantibioticsdermatologicalophthalmologicalotological and homeopathic medicinesmedicines for animal health and other medicines for the defense and protection of human and veterinary health
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
17/02/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/12/2025
PUBO
PUBLISHED FOR OPPOSITION
30/12/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
24/12/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/12/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
03/12/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/12/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
03/12/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/12/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/12/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/12/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/12/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
26/11/2025
GNRT
NON-FINAL ACTION E-MAILED
26/11/2025
CNRT
NON-FINAL ACTION WRITTEN
26/11/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/11/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/11/2025
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
25/11/2025
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
09/09/2025
GNSI
INQUIRY TO SUSPENSION E-MAILED
09/09/2025
CNSI
SUSPENSION INQUIRY WRITTEN
09/09/2025
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
29/07/2025
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
28/01/2025
GNSL
LETTER OF SUSPENSION E-MAILED
28/01/2025
CNSL
SUSPENSION LETTER WRITTEN
28/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/01/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/01/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/01/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
15/01/2025
GNRT
NON-FINAL ACTION E-MAILED
15/01/2025
CNRT
NON-FINAL ACTION WRITTEN
15/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/01/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/01/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/01/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
30/10/2024
GNRT
NON-FINAL ACTION E-MAILED
30/10/2024
CNRT
NON-FINAL ACTION WRITTEN
30/10/2024
DOCK
ASSIGNED TO EXAMINER
30/10/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/10/2024
NWAP
NEW APPLICATION ENTERED
17/04/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace GENFAR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.